Company: STAA
Filing Date: 2025-10-06
Form Type: DEFA14A
Source: 0001193125-25-230945
Chunk: 2

Company: STAAR SURGICAL CO
Filing Date: 2025-10-06
Form: DEFA14A
Chunk 2
---
 STAA story at present.” – Piper Sandler 8.5.25                                                              |

| • |     | “We do not expect a higher rival bid and expect the Alcon transaction to close in the next twelve 
 months.” – Sidoti 8.5.25                                                                          |

| • |     | “We do not expect additional bidders for STAA.” – Wells Fargo 8.5.25 |

The Alcon Transaction Provides STAAR Stockholders with Compelling, Certain, Premium Cash Value

| • |     | “We note that $28/share represents an attractive 30% premium (3.8x) to the mean 2025E EV/Sales multiple of  
 the small cap Med-Tech comp group (2.9x) applied to our 2026E revenue of $335M.” – Canaccord Genuity 8.5.25 |

| • |     | “Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash, which                                                                                            
 represents approximately a 59% premium to STAAR’s 90-day Volume Weighted Average Price (VWAP) and a 51% premium to the closing price of STAAR common stock on August 4, 2025. The transaction 
 represents a total equity value of approximately $1.5 billion (4.7x FY26 sales). STAAR shares are down 24% YTD (on weak earnings impacted by softer China demand).” – J.P. Morgan 8.5.25      |

| • |     | “The takeover price represents 6x our estimated 2025 sales and is a 51% premium to Monday’s closing 
 price or $18.49.” – Sidoti 8.5.25                                                                   |

There Are Substantial Downside Risks if the Alcon Merger Is Not Completed

| • |     | “if the deal were to fall through, we’d expect shares to respond negatively due to the limited                                                                                                                                                           
 visibility into moving past the macroeconomic challenges related to China and the current acquisition premium baked into the stock fading. After STAA announced the substantial surprise 4Q24 miss due to inventory challenges in China, shares bottomed 
 at 2x revenue, which we believe was due to the Company being viewed as a potential takeout target. While we do admit the timing of the deal is not ideal for STAA, we view the proposed merger as its best path forward in the current                   
 environment.” –